Frankfurt
31.08.26 | 15:41
0,009 Euro
+500,00 % +0,008
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,003 | 0,009 | 31.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Verici Dx PLC - Holding(s) in Company | - | RNS | ||
| 11.08. | Verici Dx PLC - Certified Service Provider agreement with Olink | - | RNS | ||
| 04.08. | Verici Dx PLC - Holding(s) in Company | - | RNS | ||
| VERICI DX Aktie jetzt für 0€ handeln | |||||
| 28.07. | Verici Dx PLC - Result of AGM | - | RNS | ||
| 06.07. | Verici Dx PLC - Investor presentation | - | RNS | ||
| 01.07. | Verici Dx PLC - Holding(s) in Company | - | RNS | ||
| 29.06. | Verici Dx PLC - Final results for the year ended 31 December 2025 | - | RNS | ||
| 25.06. | Verici Dx PLC - Holding(s) in Company | 2 | RNS | ||
| 24.06. | Verici Dx receives New York lab certification for transplant test | 1 | Investing.com | ||
| 24.06. | Verici Dx: Zulassung in New York ermöglicht US-weiten Einsatz von Transplantations-Test | - | Investing.com Deutsch | ||
| 24.06. | Verici Dx PLC - New York State clinical lab certification received | - | RNS | ||
| 23.06. | Verici Dx PLC - Holding(s) in Company | 1 | RNS | ||
| 22.06. | Verici Dx PLC - Result of General Meeting | - | RNS | ||
| 19.06. | Verici Dx PLC - Holding(s) in Company | 1 | RNS | ||
| 12.06. | Verici Dx raises additional £0.19m through retail offer | 2 | Sharecast | ||
| 12.06. | Verici Dx PLC - Result of WRAP Retail Offer | - | RNS | ||
| 08.06. | Verici Dx beruft Hauptversammlung zur Aktienausgabe ein | 1 | Investing.com Deutsch | ||
| 08.06. | Verici Dx schedules shareholder meeting on share issuance | 1 | Investing.com | ||
| 08.06. | Verici Dx PLC - Publication of Circular & Notice of GM | - | RNS | ||
| 08.06. | Verici Dx PLC - WRAP Retail Offer for up to £200,000 | - | RNS |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 25,430 | 0,00 % | Biotech Stocks At 52-Week Highs - Alamar Biosciences +30% on Q2 Reports, Dyne Therapeutics, Cullinan Therapeutics, DexCom, Cardinal Health | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports.Alamar Biosciences Inc.... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,840 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| QIAGEN | 37,235 | -0,94 % | QIAGEN profitiert von neuen Spekulationen: QIAGEN Aktie zieht wieder an Übernahmegespräche sorgen für frischen Rückenwind | Die QIAGEN Aktie erholt sich nach zwei schwächeren Handelstagen wieder. Neue Spekulationen über mögliche Übernahmegespräche sorgen am Markt für Kaufinteresse.Übernahmefantasie treibt den Kurs Die QIAGEN... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 135,06 | -0,02 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| VOR BIOPHARMA | 22,480 | 0,00 % | Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 349,94 | -0,10 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DAMORA THERAPEUTICS | 28,180 | 0,00 % | Damora Therapeutics, Inc.: Damora Announces Redomestication from Delaware to Cayman Islands | BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 33,740 | -0,03 % | Guggenheim raises Amylyx stock price target on financing, trial data | ||
| ERASCA | 17,855 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 126,95 | +0,20 % | Citizens reiterates Market Perform on Inhibrx Biosciences stock | ||
| COGENT BIOSCIENCES | 34,980 | -0,06 % | $100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today | ||
| RELAY THERAPEUTICS | 18,350 | -0,16 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| CG ONCOLOGY | 75,19 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,620 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 87,45 | +0,06 % | Zahlen stark, Bewertung billig: Zwar nicht BioNTech oder Moderna, aber auch dieses Unternehmen hat geliefert! | © Foto: Google GeminiZuletzt sorgten vor allem Biotechnologie-Werte für Schlagzeilen, doch auch klassische Pharmaunternehmen wie Dermapharm befinden sich in einer guten Verfassung Enthaltene Werte:... ► Artikel lesen |
VERICI DX PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,009 Euro und damit +500,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VERICI DX PLC finden Sie auf Wallstreet Online.